Antibody "Cocktail" Could Offer Potent Treatment, Prevention of COVID-19
Writing in Nature, scientists found the antibodies fell into 2 distinct groups, targeting different regions of the viral spike. Thus, they say, the battle against coronavirus disease 2019 (COVID-19) could be opened on separate fronts, much like the approach Ho and others have studied in HIV and some forms of cancer.
The scientist who changed the course of the AIDS epidemic has published findings that suggest the sickest patients who battle their way back from coronavirus disease 2019 (COVID-19) could hold a key to treating and preventing the disease, especially for elderly individuals.
David Ho, MD, scientific director of the Aaron Diamond AIDS Research Center and professor of medicine at Columbia University Vagelos College of Physicians and Surgeons, directed a team that isolated 19 antibodies from 5 patients who had been extremely ill with COVID-19. In a series of experiments, both in vitro and with hamsters, they showed how the antibodies neutralized the SARS-CoV-2 virus, which causes the disease.
Writing in Nature, the scientists found the antibodies fell into 2 distinct groups, targeting different regions of the viral spike. Thus, they say, the battle against COVID-19 could be opened on separate fronts, much like the approach Ho and others have studied in
In
The antibodies isolated in these experiments could offer a solution, Ho said. "We now have a collection of antibodies that's more potent and diverse compared to other antibodies that have been found so far, and they are ready to be developed into treatments," he said.
Knowledge gained over decades of researching HIV/AIDS is bearing fruit, as Ho has shifted his team from HIV research to a nonstop effort to find treatments for COVID-19. While plasma from recovered patients was collected from the start for use as “convalescent serum,” Ho’s team realized that not all antibodies are the same.
“We think that the sicker patients saw more virus and for a longer period of time, which allowed their immune system to mount a more robust response,” Ho said. “This is similar to what we have learned from the HIV experience.”
In 1996, Ho was named TIME Man of the Year for his work developing the HIV “cocktail,” which combined multiple drugs to battle the virus that causes AIDS “early and hard,” thus rendering what had been a death sentence into a chronic condition. In the Nature article, Ho and his co-authors conceived an antibody cocktail, which would use different types of antibodies directed at different locations on the familiar “spike” on SARS-CoV-2 that gives the virus its “corona.” The most potent antibodies isolated in the research targeted 1 of 2 locations: either the receptor binding domain, which allows the virus to attach to human cells, or the N-terminal region of the spike protein.
Using a cocktail of different antibodies to hit different vulnerable spots on the spike at once lowers the risk that the virus becomes resistant to treatment, Ho said. This concept of hitting dual targets is idea behind bispecific antibodies, which Ho and others have been
After confirming that the purified antibodies provide protection against SARS-CoV-2 infection in hamsters, the research team plans additional studies in animal models and in humans. “We believe several of our monoclonal antibodies with exquisite virus-neutralizing activity are promising candidates for development as modalities to treat or prevent SARS-CoV-2 infection,” they wrote.
Reference
Liu L, Wang P, Nair MS, et al. Potent neutralizing antibodies directed to multiple epitopes on SARS-CoV-2 spike. Nature. Published online July 22, 2020. doi:10.1038/s41586-020-2571-7
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Related Articles
- Rural-Urban Disparities in Colorectal Cancer Screening Persist
September 21st 2025
- AML Survival After 3 Years in Remission Comparable With General Population
September 20th 2025
- AHA Launches New Initiative to Help Patients With Heart Failure
September 20th 2025
- CSU More Burdensome in Female Patients, Especially in Midlife
September 20th 2025
- Pirtobrutinib Shows Clinically Meaningful PFS Improvement in Frontline CLL
September 19th 2025